The Lubrizol Corporation has formed an alliance between Lubrizol LifeSciences, a supplier of advanced materials for the healthcare industry, and Particle Sciences, an integrated provider of drug development services. This alliance is designed to offer customers a comprehensive solution providing a range of materials, drug development and commercial manufacturing services.

Lubrizol’s recent acquisition of contract manufacturer Vesta, in combination with Lubrizol’s alliance with Particle Sciences, means that the LifeSciences business now offers complete solutions for sustained, controlled release and combination products from polymer supply and drug product development through quality manufacturing services.

“We’ve broadened our offering and further reinforced our commitment to the pharmaceutical market,” said Jean Claude Deneuville, Lubrizol LifeSciences director of the Pharma Solutions business. “By joining forces with Vesta and working with Particle Sciences, we have further expanded our set of skills and brought full-service solutions to the market.” Lubrizol LifeSciences now offers a combination of polymer technology, drug product development services, clinical supply, applications know-how and commercial manufacturing.

“Teaming up with both Vesta and Particle Sciences enables Lubrizol to leverage our core polymer chemistry into tailored solutions for novel implantable and dermal drug delivery systems and combination products to deliver improved patient outcomes,” says Joey Glassco, global market manager for Lubrizol LifeSciences.

Particle Sciences, based in Bethlehem, PA, is one of the world’s leading contract drug development and manufacturing organizations (CDMO) with a full suite of services including analytic, bio-analytic, physical characterization and manufacturing, all focused on the formulation and support of advanced drug delivery solutions. The company says its position in drug eluting product development and breadth of development technologies has earned it business with life sciences companies ranging from start-ups to more than half of the top 10 pharmaceutical and biotech leaders.